Imaging-based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy

Ahmed M. Amer; Mohamed Zaid; Baishali Chaudhury; Dalia Elganainy; Yeonju Lee; Christopher T. Wilke; Jordan Cloyd; Huamin Wang; Anirban Maitra; Robert A. Wolff; Gauri Varadhachary; Michael J. Overman; Jeffery E. Lee; Jason B. Fleming; Ching Wei Tzeng; Matthew H. Katz; Emma B. Holliday; Sunil Krishnan; Bruce D. Minsky; Joseph M. Herman; Cullen M. Taniguchi; Prajnan Das; Christopher H. Crane; Ott Le; Priya Bhosale; Eric P. Tamm; Eugene J. Koay

doi:10.1002/cncr.31251

Imaging-based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy

Ahmed M. Amer, Mohamed Zaid, Baishali Chaudhury, Dalia Elganainy, Yeonju Lee, Christopher T. Wilke, Jordan Cloyd, Huamin Wang, Anirban Maitra, Robert A. Wolff, Gauri Varadhachary, Michael J. Overman, Jeffery E. Lee, Jason B. Fleming, Ching Wei Tzeng, Matthew H. Katz, Emma B. Holliday, Sunil Krishnan, Bruce D. Minsky, Joseph M. HermanCullen M. Taniguchi, Prajnan Das, Christopher H. Crane, Ott Le, Priya Bhosale, Eric P. Tamm, Eugene J. Koay

Research output: Contribution to journal › Article › peer-review

34 Scopus citations

Abstract

BACKGROUND: The assessment of pancreatic ductal adenocarcinoma (PDAC) response to therapy remains challenging. The objective of this study was to investigate whether changes in the tumor/parenchyma interface are associated with response. METHODS: Computed tomography (CT) scans before and after therapy were reviewed in 4 cohorts: cohort 1 (99 patients with stage I/II PDAC who received neoadjuvant chemoradiation and surgery); cohort 2 (86 patients with stage IV PDAC who received chemotherapy), cohort 3 (94 patients with stage I/II PDAC who received protocol-based neoadjuvant gemcitabine chemoradiation), and cohort 4 (47 patients with stage I/II PDAC who received neoadjuvant chemoradiation and were prospectively followed in a registry). The tumor/parenchyma interface was visually classified as either a type I response (the interface remained or became well defined) or a type II response (the interface became poorly defined) after therapy. Consensus (cohorts 1-3) and individual (cohort 4) visual scoring was performed. Changes in enhancement at the interface were quantified using a proprietary platform. RESULTS: In cohort 1, type I responders had a greater probability of achieving a complete or near-complete pathologic response (21% vs 0%; P =.01). For cohorts 1, 2, and 3, type I responders had significantly longer disease-free and overall survival, independent of traditional covariates of outcomes and of baseline and normalized cancer antigen 19-9 levels. In cohort 4, 2 senior radiologists achieved a κ value of 0.8, and the interface score was associated with overall survival. The quantitative method revealed high specificity and sensitivity in classifying patients as type I or type II responders (with an area under the receiver operating curve of 0.92 in cohort 1, 0.96 in cohort 2, and 0.89 in cohort 3). CONCLUSIONS: Changes at the PDAC/parenchyma interface may serve as an early predictor of response to therapy. Cancer 2018;124:1701-9.

Original language	English (US)
Pages (from-to)	1701-1709
Number of pages	9
Journal	Cancer
Volume	124
Issue number	8
DOIs	https://doi.org/10.1002/cncr.31251
State	Published - Apr 15 2018
Externally published	Yes

Keywords

Response Evaluation Criteria in Solid Tumors (RECIST)
cytotoxic therapy
imaging biomarker
pancreatic cancer
response

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1002/cncr.31251

Cite this

Amer, A. M., Zaid, M., Chaudhury, B., Elganainy, D., Lee, Y., Wilke, C. T., Cloyd, J., Wang, H., Maitra, A., Wolff, R. A., Varadhachary, G., Overman, M. J., Lee, J. E., Fleming, J. B., Tzeng, C. W., Katz, M. H., Holliday, E. B., Krishnan, S., Minsky, B. D., ... Koay, E. J. (2018). Imaging-based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy. Cancer, 124(8), 1701-1709. https://doi.org/10.1002/cncr.31251

Amer, AM, Zaid, M, Chaudhury, B, Elganainy, D, Lee, Y, Wilke, CT, Cloyd, J, Wang, H, Maitra, A, Wolff, RA, Varadhachary, G, Overman, MJ, Lee, JE, Fleming, JB, Tzeng, CW, Katz, MH, Holliday, EB, Krishnan, S, Minsky, BD, Herman, JM, Taniguchi, CM, Das, P, Crane, CH, Le, O, Bhosale, P, Tamm, EP & Koay, EJ 2018, 'Imaging-based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy', Cancer, vol. 124, no. 8, pp. 1701-1709. https://doi.org/10.1002/cncr.31251

@article{4730ca5fdd224e32b2f34c06f6317b89,

title = "Imaging-based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy",

abstract = "BACKGROUND: The assessment of pancreatic ductal adenocarcinoma (PDAC) response to therapy remains challenging. The objective of this study was to investigate whether changes in the tumor/parenchyma interface are associated with response. METHODS: Computed tomography (CT) scans before and after therapy were reviewed in 4 cohorts: cohort 1 (99 patients with stage I/II PDAC who received neoadjuvant chemoradiation and surgery); cohort 2 (86 patients with stage IV PDAC who received chemotherapy), cohort 3 (94 patients with stage I/II PDAC who received protocol-based neoadjuvant gemcitabine chemoradiation), and cohort 4 (47 patients with stage I/II PDAC who received neoadjuvant chemoradiation and were prospectively followed in a registry). The tumor/parenchyma interface was visually classified as either a type I response (the interface remained or became well defined) or a type II response (the interface became poorly defined) after therapy. Consensus (cohorts 1-3) and individual (cohort 4) visual scoring was performed. Changes in enhancement at the interface were quantified using a proprietary platform. RESULTS: In cohort 1, type I responders had a greater probability of achieving a complete or near-complete pathologic response (21% vs 0%; P =.01). For cohorts 1, 2, and 3, type I responders had significantly longer disease-free and overall survival, independent of traditional covariates of outcomes and of baseline and normalized cancer antigen 19-9 levels. In cohort 4, 2 senior radiologists achieved a κ value of 0.8, and the interface score was associated with overall survival. The quantitative method revealed high specificity and sensitivity in classifying patients as type I or type II responders (with an area under the receiver operating curve of 0.92 in cohort 1, 0.96 in cohort 2, and 0.89 in cohort 3). CONCLUSIONS: Changes at the PDAC/parenchyma interface may serve as an early predictor of response to therapy. Cancer 2018;124:1701-9.",

keywords = "Response Evaluation Criteria in Solid Tumors (RECIST), cytotoxic therapy, imaging biomarker, pancreatic cancer, response",

author = "Amer, {Ahmed M.} and Mohamed Zaid and Baishali Chaudhury and Dalia Elganainy and Yeonju Lee and Wilke, {Christopher T.} and Jordan Cloyd and Huamin Wang and Anirban Maitra and Wolff, {Robert A.} and Gauri Varadhachary and Overman, {Michael J.} and Lee, {Jeffery E.} and Fleming, {Jason B.} and Tzeng, {Ching Wei} and Katz, {Matthew H.} and Holliday, {Emma B.} and Sunil Krishnan and Minsky, {Bruce D.} and Herman, {Joseph M.} and Taniguchi, {Cullen M.} and Prajnan Das and Crane, {Christopher H.} and Ott Le and Priya Bhosale and Tamm, {Eric P.} and Koay, {Eugene J.}",

note = "Publisher Copyright: {\textcopyright} 2018 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society",

year = "2018",

month = apr,

day = "15",

doi = "10.1002/cncr.31251",

language = "English (US)",

volume = "124",

pages = "1701--1709",

journal = "Cancer",

issn = "0008-543X",

publisher = "John Wiley and Sons Inc.",

number = "8",

}

TY - JOUR

T1 - Imaging-based biomarkers

T2 - Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy

AU - Amer, Ahmed M.

AU - Zaid, Mohamed

AU - Chaudhury, Baishali

AU - Elganainy, Dalia

AU - Lee, Yeonju

AU - Wilke, Christopher T.

AU - Cloyd, Jordan

AU - Wang, Huamin

AU - Maitra, Anirban

AU - Wolff, Robert A.

AU - Varadhachary, Gauri

AU - Overman, Michael J.

AU - Lee, Jeffery E.

AU - Fleming, Jason B.

AU - Tzeng, Ching Wei

AU - Katz, Matthew H.

AU - Holliday, Emma B.

AU - Krishnan, Sunil

AU - Minsky, Bruce D.

AU - Herman, Joseph M.

AU - Taniguchi, Cullen M.

AU - Das, Prajnan

AU - Crane, Christopher H.

AU - Le, Ott

AU - Bhosale, Priya

AU - Tamm, Eric P.

AU - Koay, Eugene J.

PY - 2018/4/15

Y1 - 2018/4/15

N2 - BACKGROUND: The assessment of pancreatic ductal adenocarcinoma (PDAC) response to therapy remains challenging. The objective of this study was to investigate whether changes in the tumor/parenchyma interface are associated with response. METHODS: Computed tomography (CT) scans before and after therapy were reviewed in 4 cohorts: cohort 1 (99 patients with stage I/II PDAC who received neoadjuvant chemoradiation and surgery); cohort 2 (86 patients with stage IV PDAC who received chemotherapy), cohort 3 (94 patients with stage I/II PDAC who received protocol-based neoadjuvant gemcitabine chemoradiation), and cohort 4 (47 patients with stage I/II PDAC who received neoadjuvant chemoradiation and were prospectively followed in a registry). The tumor/parenchyma interface was visually classified as either a type I response (the interface remained or became well defined) or a type II response (the interface became poorly defined) after therapy. Consensus (cohorts 1-3) and individual (cohort 4) visual scoring was performed. Changes in enhancement at the interface were quantified using a proprietary platform. RESULTS: In cohort 1, type I responders had a greater probability of achieving a complete or near-complete pathologic response (21% vs 0%; P =.01). For cohorts 1, 2, and 3, type I responders had significantly longer disease-free and overall survival, independent of traditional covariates of outcomes and of baseline and normalized cancer antigen 19-9 levels. In cohort 4, 2 senior radiologists achieved a κ value of 0.8, and the interface score was associated with overall survival. The quantitative method revealed high specificity and sensitivity in classifying patients as type I or type II responders (with an area under the receiver operating curve of 0.92 in cohort 1, 0.96 in cohort 2, and 0.89 in cohort 3). CONCLUSIONS: Changes at the PDAC/parenchyma interface may serve as an early predictor of response to therapy. Cancer 2018;124:1701-9.

AB - BACKGROUND: The assessment of pancreatic ductal adenocarcinoma (PDAC) response to therapy remains challenging. The objective of this study was to investigate whether changes in the tumor/parenchyma interface are associated with response. METHODS: Computed tomography (CT) scans before and after therapy were reviewed in 4 cohorts: cohort 1 (99 patients with stage I/II PDAC who received neoadjuvant chemoradiation and surgery); cohort 2 (86 patients with stage IV PDAC who received chemotherapy), cohort 3 (94 patients with stage I/II PDAC who received protocol-based neoadjuvant gemcitabine chemoradiation), and cohort 4 (47 patients with stage I/II PDAC who received neoadjuvant chemoradiation and were prospectively followed in a registry). The tumor/parenchyma interface was visually classified as either a type I response (the interface remained or became well defined) or a type II response (the interface became poorly defined) after therapy. Consensus (cohorts 1-3) and individual (cohort 4) visual scoring was performed. Changes in enhancement at the interface were quantified using a proprietary platform. RESULTS: In cohort 1, type I responders had a greater probability of achieving a complete or near-complete pathologic response (21% vs 0%; P =.01). For cohorts 1, 2, and 3, type I responders had significantly longer disease-free and overall survival, independent of traditional covariates of outcomes and of baseline and normalized cancer antigen 19-9 levels. In cohort 4, 2 senior radiologists achieved a κ value of 0.8, and the interface score was associated with overall survival. The quantitative method revealed high specificity and sensitivity in classifying patients as type I or type II responders (with an area under the receiver operating curve of 0.92 in cohort 1, 0.96 in cohort 2, and 0.89 in cohort 3). CONCLUSIONS: Changes at the PDAC/parenchyma interface may serve as an early predictor of response to therapy. Cancer 2018;124:1701-9.

KW - Response Evaluation Criteria in Solid Tumors (RECIST)

KW - cytotoxic therapy

KW - imaging biomarker

KW - pancreatic cancer

KW - response

UR - http://www.scopus.com/inward/record.url?scp=85041104594&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041104594&partnerID=8YFLogxK

U2 - 10.1002/cncr.31251

DO - 10.1002/cncr.31251

M3 - Article

C2 - 29370450

AN - SCOPUS:85041104594

SN - 0008-543X

VL - 124

SP - 1701

EP - 1709

JO - Cancer

JF - Cancer

IS - 8

ER -

Imaging-based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this